Slideshow
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
This slideshow reviews drug information for IRESSA (gefitinib), indicated for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
Table of Contents
Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 20: Clinical Safety and EfficacySlide 25: Drug Storage and SupplySlide 27: References